Clearmind Medicine Inc.

Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on developing new psychedelic medicines for various health issues. The company is developing treatments for alcohol use disorders, binge drinking, eating disorders, weight loss, obesity, metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment-resistant depression. Its key product, the MEAI compound, is being developed for alcohol use disorder, obesity, and metabolic disorders, and also as an alcohol substitute consumer product. Another product, CM-CMND-001, is currently in a Phase I/IIa clinical trial for the treatment of alcohol use disorder. Clearmind Medicine Inc. collaborates with other entities on various projects. It has a collaboration with SciSparc Ltd. to study a combination treatment for obesity and metabolic syndrome. The company also works with Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds for post-traumatic stress disorder and other health conditions. Additionally, Clearmind Medicine Inc. collaborates with Polyrizon Ltd. to develop a new intranasal MEAI formulation and with NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was incorporated in 2017, was formerly known as Cyntar Ventures Inc., and changed its name to Clearmind Medicine Inc. in March 2021. It is headquartered in Vancouver, Canada.